Section Arrow
Quote
VRTX.NASDAQ
- Vertex Pharmaceuticals
Quotes are at least 15-min delayed:2026/11/07 01:02 EST
Regular Hours
Last
 547.09
+4.59 (+0.85%)
Day High 
548.76 
Prev. Close
542.5 
1-M High
568.6699 
Volume 
1.27M 
Bid
531.33
Ask
569
Day Low
531.53 
Open
531.53 
1-M Low
484.08 
Market Cap 
137.54B 
Currency 美元 
P/E 34.91 
%Yield -- 
10-SMA 536.65 
20-SMA 522.6 
50-SMA 522.81 
52-W High 568.6699 
52-W Low 410.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
15.54/21.49
Enterprise Value
139.50B
Balance Sheet
Book Value Per Share
82.46
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
11.02B
Operating Revenue Per Share
38.08
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
CDTCdt Equity Inc1.31+0.464+54.85%0PE
MRNAModerna254.19+12.73+5.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.